Phathom Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ, 07932
Mailing Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ, 07932
Phone
(877) 742-8466
Fiscal Year End
1231
EIN
824151574
Financial Overview
FY2025 FY
$175.11M
Revenue
$378.32M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 10-K Annual financial report | February 26, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 27, 2026 | View on SEC |
| 4 Insider stock transaction report | January 27, 2026 | View on SEC |
| 4 Insider stock transaction report | January 23, 2026 | View on SEC |
Annual Reports
10-K
February 26, 2026
- FDA approved and successfully launched VOQUEZNA for erosive esophagitis in late 2023, driving significant revenue.
- Reported substantial net product revenue growth to $85.2 million in 2023 from $15.7 million in 2022.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.